Ident. | Authors (with country if any) | Title |
---|
000075 |
Line Kenborg [Danemark] ; Christina F. Lassen [Danemark] ; Beate Ritz [États-Unis] ; Eva S. Schernhammer [États-Unis] ; Johnni Hansen [Danemark] ; Nicole M. Gatto [États-Unis] ; J Rgen H. Olsen [Danemark] | Outdoor work and risk for Parkinson's disease: a population-based case–control study |
000117 |
Vibeke Guldbrand Rasmussen [Danemark] ; Karen Stergaard [Danemark] ; Erik Dupont [Danemark] ; Steen Hvitfeldt Poulsen [Danemark] | The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists |
000130 |
Lise Hounsgaard [Danemark] ; Birthe Pedersen [Danemark] ; Lis Wagner [Danemark] | The daily living for informal caregivers with a partner with Parkinson’s disease – an interview study of women’s experiences of care decisions and self‐management |
000223 |
Malene Flensborg Damholdt [Danemark] ; Per Borghammer [Danemark] ; Lars Larsen [Danemark] ; Karen Stergaard [Danemark] | Odor identification deficits identify Parkinson's disease patients with poor cognitive performance |
000270 |
Anita Haahr [Danemark] ; Marit Kirkevold [Norvège] ; Elisabeth O. C. Hall [Danemark] ; Karen Stergaard [Danemark] | Living with advanced Parkinson’s disease: a constant struggle with unpredictability |
000276 |
Lazlo Horvath [Suède] ; Ingrid Van Marion [Suède] ; Khalid Taï [Suède] ; Troels Tolstrup Nielsen [Danemark] ; Cecilia Lundberg [Suède] | Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease |
000475 |
Zhen Hong [États-Unis, République populaire de Chine] ; Min Shi [États-Unis] ; Kathryn A. Chung [États-Unis] ; Joseph F. Quinn [États-Unis] ; Elaine R. Peskind [États-Unis] ; Douglas Galasko [États-Unis] ; Joseph Jankovic [États-Unis] ; Cyrus P. Zabetian [États-Unis] ; James B. Leverenz [États-Unis] ; Geoffrey Baird [États-Unis] ; Thomas J. Montine [États-Unis] ; Aneeka M. Hancock [États-Unis] ; Hyejin Hwang [États-Unis] ; Catherine Pan [États-Unis] ; Joshua Bradner [États-Unis] ; Un J. Kang [États-Unis] ; Poul H. Jensen [Danemark] ; Jing Zhang [États-Unis] | DJ-1 and -synuclein in human cerebrospinal fluid as biomarkers of Parkinsons disease |
000535 |
Beate Ritz [États-Unis] ; Angelika D. Manthripragada [États-Unis] ; Lei Qian [États-Unis] ; Eva Schernhammer [États-Unis] ; Lene Wermuth [Danemark] ; Jorgen Olsen [Danemark] ; Soren Friis [Danemark] | Statin use and Parkinson's disease in Denmark |
000547 |
Hanne Madsen [Danemark] ; Kim Brixen [Danemark] ; Jesper Hallas [Danemark] | Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease – a population‐based database study |
000551 |
Kathrine Rugbjerg [Danemark] ; S Ren Friis [Danemark] ; Thomas L. J Rgensen [Danemark] ; Beate Ritz [États-Unis] ; Lise Korbo [Danemark] ; J Rgen H. Olsen [Danemark] | Risk for Parkinson's disease among patients with osteoarthritis: A Danish cohort study |
000650 |
E. L. Johnsen ; N. Sunde ; P. H. Mogensen [Danemark] ; K. Stergaard | MRI verified STN stimulation site – gait improvement and clinical outcome |
000651 |
Beate Ritz [États-Unis] ; Shannon L. Rhodes [États-Unis] ; Lei Qian [États-Unis] ; Eva Schernhammer [États-Unis] ; J Rgen H. Olsen [Danemark] ; S Ren Friis [Danemark] | L‐type calcium channel blockers and Parkinson disease in Denmark |
000766 |
Ayse Ulusoy [Suède] ; Fabia Febbraro [Danemark] ; Poul H. Jensen [Danemark] ; Deniz Kirik [Suède] ; Marina Romero-Ramos [Suède, Danemark] | Co‐expression of C‐terminal truncated alpha‐synuclein enhances full‐length alpha‐synuclein‐induced pathology |
000790 |
Steven R. Schwid [États-Unis] ; Janice Bausch [États-Unis] ; David Oakes [États-Unis] ; Lynn Schuchter [États-Unis] ; Caroline Tanner [États-Unis] ; Misser Forrest [Danemark] ; Anthony E. Lang [Canada] ; Ira Shoulson [États-Unis] | Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease |
000842 |
P. Borghammer [Danemark] ; K. Stergaard [Danemark] ; P. Cumming [Allemagne] ; A. Gjedde [Danemark] ; A. Rodell [Danemark] ; N. Hall [Danemark] ; M. M. Chakravarty [Danemark, États-Unis] | A deformation‐based morphometry study of patients with early‐stage Parkinson’s disease |
000892 |
Katerina E. Paleologou [Royaume-Uni] ; Christine L. Kragh [Danemark] ; David M. A. Mann [Royaume-Uni] ; Sultan A. Salem [Royaume-Uni] ; Rania Al-Shami [Émirats arabes unis] ; David Allsop [Royaume-Uni] ; Ahmed H. Hassan [Émirats arabes unis] ; Poul H. Jensen [Danemark] ; Omar M. A. El-Agnaf [Émirats arabes unis] | Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies |
000964 |
Jacob Geday [Danemark] ; Karen Stergaard [Danemark] ; Erik Johnsen [Danemark] ; Albert Gjedde [Danemark] | STN‐stimulation in Parkinson's disease restores striatal inhibition of thalamocortical projection |
000A37 |
Bart F. L. Van Nuenen [Pays-Bas, Allemagne] ; Thilo Van Eimeren [Canada] ; Joyce P. M. Van Der Vegt [Pays-Bas, Allemagne] ; Carsten Buhmann [Allemagne] ; Christine Klein [Allemagne] ; Bastiaan R. Bloem [Pays-Bas] ; Hartwig R. Siebner [Allemagne, Danemark] | Mapping preclinical compensation in Parkinson's disease: An imaging genomics approach |
000A63 |
Erik L. Johnsen [Danemark] ; Poul H. Mogensen [Danemark] ; Niels Aa. Sunde [Danemark] ; Karen Stergaard [Danemark] | Improved asymmetry of gait in Parkinson's disease with DBS: Gait and postural instability in Parkinson's disease treated with bilateral deep brain stimulation in the subthalamic nucleus |
000F20 |
J Rgen H. Olsen [Danemark] ; Karina Tangerud [Danemark] ; Lene Wermuth [Danemark] ; Kirsten Frederiksen [Danemark] ; S Ren Friis [Danemark] | Treatment with levodopa and risk for malignant melanoma |
000F22 |
Morten L. Kringelbach [Royaume-Uni, Danemark] ; Ned Jenkinson [Royaume-Uni] ; Sarah L. F. Owen [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] | Translational principles of deep brain stimulation |
000F68 |
G. Waldemar [Danemark] ; B. Dubois [France] ; M. Emre [Turquie] ; J. Georges [Luxembourg (pays)] ; I. G. Mckeith [Royaume-Uni] ; M. Rossor [Royaume-Uni] ; P. Scheltens [Pays-Bas] ; P. Tariska [Hongrie] ; B. Winblad [Suède] | Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline |
001079 |
M. Brandt-Christensen ; A. G. Lopez [Danemark] ; F. M. Nilsson [Danemark] ; P. K. Andersen [Danemark] ; L. V. Kessing | Depressive disorders and anti‐parkinson drug treatment: a case register study |
001221 |
Felix Geser [Autriche] ; Gregor K. Wenning [Autriche] ; Klaus Seppi [Autriche] ; Michaela Stampfer-Kountchev [Autriche] ; Christoph Scherfler [Autriche] ; Martin Sawires [Autriche] ; Carolin Frick [Autriche] ; Jean-Pierre Ndayisaba [Autriche] ; Hanno Ulmer [Autriche] ; Maria T. Pellecchia [Italie] ; Paolo Barone [Italie] ; Hee T. Kim [Royaume-Uni] ; Juzar Hooker [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; Adriana Cardozo [Espagne] ; Eduardo Tolosa [Espagne] ; Michael Abele [Allemagne] ; Thomas Klockgether [Allemagne] ; Karen Stergaard [Danemark] ; Erik Dupont [Danemark] ; Nicole Schimke [Allemagne] ; Karla M. Eggert [Allemagne] ; Wolfgang Oertel [Allemagne] ; Ruth Djaldetti [Israël] ; Werner Poewe [Autriche] | Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG) |
001224 |
Kristian Winge [Danemark] ; Anne-Marie Skau [Danemark] ; Hans Stimpel [Danemark] ; Kurt K. Nielsen [Danemark] ; Lene Werdelin [Danemark] | Prevalence of bladder dysfunction in Parkinsons disease |
001265 |
J. M. Hertz [Danemark] ; K. Stergaard [Danemark] ; I. Juncker [Danemark] ; S. Pedersen [Danemark] ; A. Romstad [Danemark] ; L. B. M Ller [Danemark] ; F. Güttler [Danemark] ; E. Dupont [Danemark] | Low frequency of Parkin, Tyrosine Hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of early‐onset Parkinson's Disease |
001432 |
K. Winge [Danemark] ; L. Friberg [Danemark] ; L. Werdelin [Danemark] ; K. K. Nielsen [Danemark] ; H. Stimpel [Danemark] | Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease |
001457 |
Kamilla M. Pedersen [Danemark] ; Lisbeth Marner [Danemark] ; Henning Pakkenberg [Danemark] ; Bente Pakkenberg [Danemark] | No global loss of neocortical neurons in parkinson's disease: A quantitative stereological study |
001646 |
Kristian Winge [Danemark] ; Lene M. Werdelin [Danemark] ; Kurt K. Nielsen [Danemark] ; Hans Stimpel [Danemark] | Effects of dopaminergic treatment on bladder function in Parkinson's disease |
001747 |
Carl Rosenblad [Danemark] ; Biljana Georgievska [Suède] ; Deniz Kirik [Suède] | Long‐term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system |
001858 |
Julie Lotharius [Suède, Danemark] ; Patrik Brundin [Suède] | Pathogenesis of parkinson's disease: dopamine, vesicles and -synuclein |
001878 |
Flemming M. Nilsson ; Lars V. Kessing ; Tine M. S Rensen [Danemark] ; Per K. Andersen [Danemark] ; Tom G. Bolwig | Major depressive disorder in Parkinson's disease: a register‐based study |
001886 |
Helle Just [Danemark] ; Karen Ostergaard [Danemark] | Health‐Related quality of life in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nuclei |
001899 |
Karen Stergaard [Danemark] ; Niels Sunde [Danemark] ; Erik Dupont [Danemark] | Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations |
001B58 |
A. Björklund [Suède] ; D. Kirik [Suède] ; C. Rosenblad [Danemark] ; B. Georgievska [Suède] ; C. Lundberg [Suède] ; R. J. Mandel [États-Unis] | Towards a neuroprotective gene therapy for Parkinson’s disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model |
001C56 |
Carolin Banerjee ; Jens R. Nyengaard [Danemark] ; Andrea Wevers ; Rob A. I. De Vos [Pays-Bas] ; Ernst N. H. Jansen Steur [Pays-Bas] ; Jon Lindstrom ; Kirsten Pilz ; Sonja Nowacki ; Wilhelm Bloch ; Hannsjörg Schröder | Cellular Expression of α7 Nicotinic Acetylcholine Receptor Protein in the Temporal Cortex in Alzheimer's and Parkinson's Disease— A Stereological Approach |
001C89 |
M. Mikkelsen [Danemark] ; A. M Ller [Danemark] ; L. H Jensen [Danemark] ; A. Pedersen [Danemark] ; J. Berg Harajehi [Danemark] ; H. Pakkenberg [Danemark] | MPTP-Induced Parkinsonism in Minipigs |
001F84 |
Larsen [Norvège] ; Jette Boas [Danemark] | The effects of early selegiline therapy on long‐term levodopa treatment and parkinsonian disability: An interim analysis of a norwegian–danish 5‐year study |
002100 |
Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] ; Joachim Peter Steinbach [Allemagne] ; Vibke Petersen [Danemark] ; Lechoslaw Turski [Allemagne] ; Peter-Andreas Löschmann [Allemagne] | Effects of the antiparkinsonian drug budipine on central neurotransmitter systems |
002129 |
J. Boas [Danemark] ; J. Worm-Petersen [Danemark] ; E. Dupont [Danemark] ; B. Mikkelsen [Danemark] ; L. Wermuth [Danemark] | The levodopa dose‐sparing capacity of pergolide compared with that of bromocriptine in an open‐label, crossover study |
002213 |
Edith Sim [Royaume-Uni] ; Lesley A. Stanley [Royaume-Uni] ; Angela Risch [Royaume-Uni] ; Peter Thygesen [Danemark] | Xenogenetics in multifactorial disease susceptibility |
002309 |
L. Wermuth [Danemark] ; E. N. Stenager [Danemark] ; E. Stenager [Danemark] ; J. Boldsen [Danemark] | Mortality in patients with Parkinson's disease |
002448 |
J. P. Larsen [Norvège] ; E. Dupont [Danemark] ; E. Tandberg [Norvège] | Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence |
002506 |
T. Klockgether [Allemagne] ; P. Jacobsen [Danemark] ; -A. Löschmann [Allemagne] ; L. Turski [Allemagne] | The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist |
002729 |
G. Daugaard [Danemark] ; H. H. Hansen [Danemark] ; M. R Rth [Danemark] | Treatment of malignant germ cell tumors |
002817 |
I. C. Dissing [Danemark] ; F. Güttler [Danemark] ; H. Pakkenberg [Danemark] ; H. Lou [Danemark] ; A. Gerdes [Danemark] ; C. Lykkelund [Danemark] ; V. Rasmussen [Danemark] | Tetrahydrobiopterin and Parkinson's disease |
002830 |
Mikael Bitsch [Danemark] ; Christoffer Johansen [Danemark] ; Alf Wennevold [Danemark] ; Mogens Osler [Danemark] | Maternal Heart Disease |
002914 |
A. C. Johannessen [Danemark] ; A. Boye [Danemark] ; H. Pakkenberg [Danemark] | Thyroid function in patients with Parkinson's disease |
002989 |
P. Nilsson [Suède] ; F. Melsen [Danemark] ; J. Malmaeus [Suède] ; B. G. Danielson [Suède] ; L. Mosekilde [Danemark] | Relationships between calcium and phosphorus homeostasis, parathyroid hormone levels, bone aluminum, and bone histomorphometry in patients on maintenance hemodialysis |
002C22 |
Jes Gerlach [Danemark] | Relationship between tardive dyskinesia, l -Dopa-induced hyperkinesia and parkinsonism |
002C28 |
V. Kristensen [Danemark] ; M. Olsen [Danemark] ; A. Theilgaard [Danemark] | Levodopa treatment of presenile dementia |
002C46 |
Jes Gerlach [Danemark] | EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL |
002C58 |
K. Rinne [Finlande] ; E. Birket-Smith [Danemark] ; E. Dupont [Danemark] ; E. Hansen [Danemark] ; M. Hyypp [Finlande] ; R. Marttila [Finlande] ; B. Mikkelsen [Danemark] ; H. Pakkenberg [Danemark] ; J. Presthus [Norvège] | Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease |
002D15 |
Arild Faurbye [Danemark] | The structural and biochemical basis of movement disorders in treatment with neuroleptic drugs and in extrapyramidal diseases |